Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, et al. Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology. 2020;94:e1027-39. https://doi.org/10.1212/WNL.0000000000008900.

Article  PubMed  PubMed Central  Google Scholar 

Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R, et al. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2023;25(1):37-53. https://doi.org/10.1093/neuonc/noac196.

Article  PubMed  CAS  Google Scholar 

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31-42. https://doi.org/10.1016/S1470-2045(18)30864-7.

Article  PubMed  CAS  Google Scholar 

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380:45-56. https://doi.org/10.1056/NEJMoa1804980.

Article  PubMed  CAS  Google Scholar 

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294-308. https://doi.org/10.1016/S0140-6736(22)00662-6.

Article  PubMed  CAS  Google Scholar 

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line therapy for large B-Cell lymphoma. N Engl J Med. 2022;386:640-54. https://doi.org/10.1056/NEJMoa2116133.

Article  PubMed  CAS  Google Scholar 

Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019;111:646-54. https://doi.org/10.1093/jnci/djz017.

Article  PubMed  CAS  Google Scholar 

Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404-19. https://doi.org/10.1158/2159-8290.CD-17-0698.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Belin C, Devic P, Ayrignac X, Dos Santos A, Paix A, Sirven-Villaros L, et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep. 2020;10:18997. https://doi.org/10.1038/s41598-020-76055-9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133:2212-21. https://doi.org/10.1182/blood-2018-12-893396.

Article  PubMed  CAS  Google Scholar 

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and neurologic toxicity Associated with Immune Effector cells. Biol Blood Marrow Transpl. 2019;25:625-38. https://doi.org/10.1016/j.bbmt.2018.12.758.

Article  CAS  Google Scholar 

Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB, et al. Anti-CD19 CAR T cells in CNS diffuse Large-B-Cell lymphoma. N Engl J Med. 2017;377:783-4. https://doi.org/10.1056/NEJMc1704610.

Article  PubMed  Google Scholar 

Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134:860-6. https://doi.org/10.1182/blood.2019001694.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ahmed G, Hamadani M, Shah NN. CAR T-cell therapy for secondary CNS DLBCL. Blood Adv. 2021;5:5626-30. https://doi.org/10.1182/bloodadvances.2021005292.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Siddiqi T, Wang X, Blanchard MS, Wagner JR, Popplewell LL, Budde LE, et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021;5:4059-63. https://doi.org/10.1182/bloodadvances.2020004106.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alcantara M, Houillier C, Blonski M, Rubio MT, Willems L, Rascalou AW, et al. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood. 2022;139:792-6. https://doi.org/10.1182/blood.2021012932.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022;139:2306-15. https://doi.org/10.1182/blood.2021014738.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Choquet S, Soussain C, Morel V, Ursu R. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma. Real-life results of the LOC network. Am J Hematol. 2024;99:1240-9. https://doi.org/10.1002/ajh.27316.

Article  PubMed  CAS  Google Scholar 

Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, et al. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro Oncol. 2023;25:2239-49. https://doi.org/10.1093/neuonc/noad118.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nayak L, Chukwueke UN, Meehan C, Redd R, Hogan S, Quant Lee E, et al. A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL). J Clin Oncol. 2024. https://doi.org/10.1200/JCO.2024.42.

Article  Google Scholar 

Yu W, Huang L, Mei H, Li Y, Niu T, Zou D, et al. Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China. J Immunother Cancer. 2024;12:e008553.

Article  PubMed  PubMed Central  Google Scholar 

Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, et al. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023;16:111. https://doi.org/10.1186/s13045-023-01508-3.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ayuk F, Gagelmann N, von Tresckow B, Wulf G, Rejeski K, Stelljes M, et al. Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study. Blood Adv. 2023;7:5316-9. https://doi.org/10.1182/bloodadvances.2023010336.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Saidy AO, Fuhrmann S, Peczynski C, Michel E, Galimard, et al. Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition. Blood. 2023;142:1031. https://doi.org/10.1182/blood-2023-174883.

Article  Google Scholar 

Alsouqi A, Ahmed G, Wang J, Cassanello G, Szabo A, Rojek AE, et al. Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: a multicenter analysis. Am J Hematol. 2024;99:1624-7. https://doi.org/10.1002/ajh.27354.

Article  PubMed  CAS  Google Scholar 

Cook MR, Dorris CS, Makambi KH, Munshi PN, Donato M, Rowley S, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7:32-9. https://doi.org/10.1182/bloodadvances.2022008525.

Article  PubMed  CAS  Google Scholar